Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission

P. Calabresi, M. De Murtas, A. Stefani, A. Pisani, G. Sancesario, N. B. Mercuri, G. Bernardi

Research output: Contribution to journalArticle

Abstract

Oxcarbazepine (OCBZ) is the keto-analogue of carbamazepine (CBZ). In humans, OCBZ is rapidly and almost completely metabolized to 10, 11-dihydro- 10-hydroxy-CBZ (GP 47779), the main metabolite responsible for the drug's antiepileptic activity. The corticostriatal pathway is involved in the propagation of epileptic discharges. We characterized the electrophysiological effects of GP 47779 on striatal neurons by making intracellular recordings from corticostriatal slices. GP 47779 (3100 μM) produced a dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). This effect was not coupled either with changes of the membrane potential of these cells or with alterations of their postsynaptic sensitivity to excitatory amino acids (EAA) suggesting a presynaptic site of action. GP 47779 reduced the current-evoked firing discharge only at concentrations >100 μM. GP 47779 did not affect the presynaptic inhibitory action of adenosine, showing that presynaptic adenosine receptors were not implicated in the GP 47779-mediated reduction of corticostriatal EPSPs. Our data indicate that GP 47779 apparently acts directly on corticostriatal terminals to reduce the release of EAA, probably by inhibiting high-voltage- activated (HVA) calcium (Ca2+) currents (described in the accompanying article). The inhibitory action of GP 47779 on corticostriatal transmission may contribute to the antiepileptic effects of this drug.

Original languageEnglish
Pages (from-to)990-996
Number of pages7
JournalEpilepsia
Volume36
Issue number10
DOIs
Publication statusPublished - 1995

Fingerprint

10,11-dihydro-10-hydroxycarbamazepine
Synaptic Transmission
Excitatory Amino Acids
Excitatory Postsynaptic Potentials
Carbamazepine
Anticonvulsants
Presynaptic Receptors
Corpus Striatum
Purinergic P1 Receptors
oxcarbazepine

Keywords

  • Epilepsy
  • Excitatory synaptic transmission
  • Glutamate
  • Intracellular recordings
  • Oxcarbazepine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. / Calabresi, P.; De Murtas, M.; Stefani, A.; Pisani, A.; Sancesario, G.; Mercuri, N. B.; Bernardi, G.

In: Epilepsia, Vol. 36, No. 10, 1995, p. 990-996.

Research output: Contribution to journalArticle

@article{9f2160e9fbc641f39b76d901385cdc5c,
title = "Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission",
abstract = "Oxcarbazepine (OCBZ) is the keto-analogue of carbamazepine (CBZ). In humans, OCBZ is rapidly and almost completely metabolized to 10, 11-dihydro- 10-hydroxy-CBZ (GP 47779), the main metabolite responsible for the drug's antiepileptic activity. The corticostriatal pathway is involved in the propagation of epileptic discharges. We characterized the electrophysiological effects of GP 47779 on striatal neurons by making intracellular recordings from corticostriatal slices. GP 47779 (3100 μM) produced a dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). This effect was not coupled either with changes of the membrane potential of these cells or with alterations of their postsynaptic sensitivity to excitatory amino acids (EAA) suggesting a presynaptic site of action. GP 47779 reduced the current-evoked firing discharge only at concentrations >100 μM. GP 47779 did not affect the presynaptic inhibitory action of adenosine, showing that presynaptic adenosine receptors were not implicated in the GP 47779-mediated reduction of corticostriatal EPSPs. Our data indicate that GP 47779 apparently acts directly on corticostriatal terminals to reduce the release of EAA, probably by inhibiting high-voltage- activated (HVA) calcium (Ca2+) currents (described in the accompanying article). The inhibitory action of GP 47779 on corticostriatal transmission may contribute to the antiepileptic effects of this drug.",
keywords = "Epilepsy, Excitatory synaptic transmission, Glutamate, Intracellular recordings, Oxcarbazepine",
author = "P. Calabresi and {De Murtas}, M. and A. Stefani and A. Pisani and G. Sancesario and Mercuri, {N. B.} and G. Bernardi",
year = "1995",
doi = "10.1111/j.1528-1157.1995.tb00957.x",
language = "English",
volume = "36",
pages = "990--996",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "10",

}

TY - JOUR

T1 - Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission

AU - Calabresi, P.

AU - De Murtas, M.

AU - Stefani, A.

AU - Pisani, A.

AU - Sancesario, G.

AU - Mercuri, N. B.

AU - Bernardi, G.

PY - 1995

Y1 - 1995

N2 - Oxcarbazepine (OCBZ) is the keto-analogue of carbamazepine (CBZ). In humans, OCBZ is rapidly and almost completely metabolized to 10, 11-dihydro- 10-hydroxy-CBZ (GP 47779), the main metabolite responsible for the drug's antiepileptic activity. The corticostriatal pathway is involved in the propagation of epileptic discharges. We characterized the electrophysiological effects of GP 47779 on striatal neurons by making intracellular recordings from corticostriatal slices. GP 47779 (3100 μM) produced a dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). This effect was not coupled either with changes of the membrane potential of these cells or with alterations of their postsynaptic sensitivity to excitatory amino acids (EAA) suggesting a presynaptic site of action. GP 47779 reduced the current-evoked firing discharge only at concentrations >100 μM. GP 47779 did not affect the presynaptic inhibitory action of adenosine, showing that presynaptic adenosine receptors were not implicated in the GP 47779-mediated reduction of corticostriatal EPSPs. Our data indicate that GP 47779 apparently acts directly on corticostriatal terminals to reduce the release of EAA, probably by inhibiting high-voltage- activated (HVA) calcium (Ca2+) currents (described in the accompanying article). The inhibitory action of GP 47779 on corticostriatal transmission may contribute to the antiepileptic effects of this drug.

AB - Oxcarbazepine (OCBZ) is the keto-analogue of carbamazepine (CBZ). In humans, OCBZ is rapidly and almost completely metabolized to 10, 11-dihydro- 10-hydroxy-CBZ (GP 47779), the main metabolite responsible for the drug's antiepileptic activity. The corticostriatal pathway is involved in the propagation of epileptic discharges. We characterized the electrophysiological effects of GP 47779 on striatal neurons by making intracellular recordings from corticostriatal slices. GP 47779 (3100 μM) produced a dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). This effect was not coupled either with changes of the membrane potential of these cells or with alterations of their postsynaptic sensitivity to excitatory amino acids (EAA) suggesting a presynaptic site of action. GP 47779 reduced the current-evoked firing discharge only at concentrations >100 μM. GP 47779 did not affect the presynaptic inhibitory action of adenosine, showing that presynaptic adenosine receptors were not implicated in the GP 47779-mediated reduction of corticostriatal EPSPs. Our data indicate that GP 47779 apparently acts directly on corticostriatal terminals to reduce the release of EAA, probably by inhibiting high-voltage- activated (HVA) calcium (Ca2+) currents (described in the accompanying article). The inhibitory action of GP 47779 on corticostriatal transmission may contribute to the antiepileptic effects of this drug.

KW - Epilepsy

KW - Excitatory synaptic transmission

KW - Glutamate

KW - Intracellular recordings

KW - Oxcarbazepine

UR - http://www.scopus.com/inward/record.url?scp=0029122730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029122730&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1157.1995.tb00957.x

DO - 10.1111/j.1528-1157.1995.tb00957.x

M3 - Article

C2 - 7555963

AN - SCOPUS:0029122730

VL - 36

SP - 990

EP - 996

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 10

ER -